James Priour Biography and Net Worth

Global biopharma and biotech business leader with drug development, portfolio strategy, commercialization, strategic partnership and CEO experience in both large and small entrepreneurial organizations. Worked in US, Europe (Western and Eastern) and Asia Pacific. Driver of growth and value creation.

What is James Priour's net worth?: The estimated net worth of James Priour is at least $26,134.05 as of April 13th, 2021. Mr. Priour owns 2,953 shares of Zymeworks stock worth more than $26,134 as of April 20th. This net worth estimate does not reflect any other investments that Mr. Priour may own. Learn More about James Priour's net worth.
How do I contact James Priour?: The corporate mailing address for Mr. Priour and other Zymeworks executives is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. Zymeworks can also be reached via phone at (302) 274-8744 and via email at [email protected]. Learn More on James Priour's contact information.
Has James Priour been buying or selling shares of Zymeworks?: James Priour has not been actively trading shares of Zymeworks during the last ninety days. Most recently, James Priour sold 950 shares of the business's stock in a transaction on Tuesday, April 13th. The shares were sold at an average price of $27.93, for a transaction totalling $26,533.50. Following the completion of the sale, the insider now directly owns 2,953 shares of the company's stock, valued at $82,477.29. Learn More on James Priour's trading history.
Who are Zymeworks' active insiders?: Zymeworks' insider roster includes Neil Josephson (Insider), Neil Klompas (CFO), Kathryn O'Driscoll (Insider), James Priour (Insider), and Ali Tehrani (CEO). Learn More on Zymeworks' active insiders.
Are insiders buying or selling shares of Zymeworks?: During the last twelve months, Zymeworks insiders bought shares 1 times. They purchased a total of 3,350,000 shares worth more than $27,202,000.00. During the last twelve months, insiders at the sold shares 7 times. They sold a total of 40,583 shares worth more than $436,263.55. The most recent insider tranaction occured on January, 8th when CFO Christopher Astle sold 1,431 shares worth more than $16,055.82. Insiders at Zymeworks own 1.2% of the company. Learn More about insider trades at Zymeworks.
Information on this page was last updated on 1/8/2024.

James Priour Insider Trading History at Zymeworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/13/2021	Sell	950	$27.93	$26,533.50	2,953

James Priour Buying and Selling Activity at Zymeworks

Zymeworks Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Today's Range

Now: $8.85

$8.65

$8.98

50 Day Range

MA: $10.76

$8.67

$12.90

2 Week Range

Now: $8.85

$6.01

$13.14

Volume

1,002,678 shs

Average Volume

569,595 shs

Market Capitalization

$624.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story